DGAP-Adhoc

4SC AG secures EUR 29 million from capital increase to finance planned clinical development programme of its cancer compound resminostat

4SC AG / Key word(s): Capital Increase/Financing

07.07.2015 22:12

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc release pursuant to Section 15 of the German Securities Trading Act
(Wertpapierhandelsgesetz, WpHG)

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE UNITED STATES,
AUSTRALIA, CANADA OR JAPAN.

4SC AG secures EUR 29 million from capital increase to finance planned
clinical development programme of its cancer compound resminostat

- Gross proceeds at the upper end of targeted volume range

- Participation of a number of new institutional investors from the US
and Europe, including Wellington Partners as new cornerstone investor

- Financing of planned clinical Phase II trial with resminostat with the
goal of achieving market approval in tumour indication CTCL secured

Planegg-Martinsried, Germany, 7 July 2015 - 4SC AG (Frankfurt, Prime
Standard: ISIN DE000A14KL72, VSC) today announced the successful completion
of its capital increase resolved on 22 June 2015 to finance its research
and development programmes in the field of cancer therapies, in particular
a planned clinical Phase II trial of its lead oncology compound resminostat
in the indication of cutaneous T-cell lymphoma (CTCL). In a cash capital
increase 7,250,000 offered shares were placed at a subscription price of
EUR 4.00 with existing shareholders in a rights issue and with selected new
institutional investors in a subsequent rump placement, which resulted in
gross issue proceeds of EUR 29 million. Thus, due to the significant demand
by new institutional investors in the rump placement, the upper end of the
targeted volume range of EUR 24-29 million could be reached.

Furthermore, a total of 1,500,000 consideration shares will be issued at
the same issue price of EUR 4.00 by way of a capital increase against
contributions in kind in order to swap a substantial portion of EUR 6
million of a shareholder loan from Santo Holding (Deutschland) GmbH into
equity.

Major shareholder Santo Holding and a number of other existing shareholders
made a significant contribution to the cash capital increase. Additionally,